Company overview
Med-X, Inc. connects field-developed products with professional, consumer, and international market pathways.
Nature-Cide is the company’s primary growth platform, supported by Thermal-Aid and Malibu Brands. The portfolio combines operating experience, product development, distribution relationships, and ongoing market expansion.
Nature-Cide
Botanical pest-management products for professional and consumer use contexts.
Explore Nature-Cide ↗ Consumer platformThermal-Aid
Reusable heating and cooling products for adults, children, and animals.
Explore Thermal-Aid ↗ Supporting brandMalibu Brands
Topical wellness products expanding the company’s consumer portfolio.
Explore Malibu Brands ↗A necessary industry in motion
Pest control is essential. The products chosen to do it may be changing.
Homes, businesses, farms, communities, and public-health programs must continue to control pests. What can change is the product selected for the job.
Professional buyers are weighing performance, resistance, application needs, environmental considerations, regulation, procurement standards, and customer preference. A new product can compete for a place inside an established, recurring market.
Resistance
EPA and CDC emphasize resistance management and the need to identify which tools remain effective.
Operational fit
Professionals need products that perform under real application conditions and established practices.
Product choice
Institutions and consumers assess ingredients, exposure, environmental effects, efficacy, and cost together.
Integrated Pest Management
Pest Control is Evolving.
Integrated Pest Management (IPM) is a major part of that evolution. IPM does not eliminate pest control or pesticides. It provides a framework for deciding how and when to control pests—combining product selection with monitoring, prevention, action thresholds, source reduction, and evaluation. Biopesticides can be a key component in maximizing an IPM strategy by expanding the range of targeted tools available.
Institutional adoption
Government, military, and public-health programs already use integrated approaches.
These sources establish the operating context. They do not endorse Nature-Cide or any Med-X, Inc. product.
Category growth
Biopesticides are becoming a larger commercial category.
Major researchers consistently project growth. The conservative forecast featured here estimates global agricultural biopesticides expanding from $6.24 billion in 2024 to $10.62 billion by 2030.
Market researchGrand View Research ↗Built and refined through field experience
From Southern California pest-control work to a broader product platform.
Nature-Cide products were field tested for years in the Santa Monica Mountains. That research and development evolved into a licensed California pest-management service practicing IPM.
Products were tested in real environments; the work supported service operations; and operating experience helped inform how the products were refined, positioned, and introduced to additional customers.
Nature-Cide grew from the work of solving pest-control problems in the field.Explore the product history ↗
From products to market pathways
A multi-channel model designed to reach professional, consumer, institutional, and international customers.
Professional distribution
Routes into purchasing systems already used by pest-management and landscape professionals.
Consumer reach
Retail, marketplaces, and direct e-commerce extend the brands to end users.
International development
Local partners combine distribution knowledge with registration work.
Service networks
Relationships connect Nature-Cide with operating pest-control businesses.
Public-health development
Nature-Cide’s next field may be larger than conventional pest management.
Med-X, Inc. reports that Nature-Cide X2 Plus has been evaluated in mosquito-control work in Florida, Georgia, and Mexico, alongside WHO-aligned evaluation and international regulatory development.
The program remains ongoing. This profile presents the work broadly and does not publish study-specific results or comparative claims.
Leadership
The management team behind the strategy.
The team combines product development, operations, finance, science, administration, media, e-commerce, and market-development experience.
Matthew A. Mills
Chief Executive Officer and ChairmanLeads corporate strategy across product development, manufacturing, operations, business development, and long-term expansion.
Jennifer J. Mills
President, Director, and Corporate SecretarySupports operating continuity across administration, accounting liaison work, HR, and project management.
Ronald J. Tchorzewski
Chief Financial Officer and DirectorOversees accounting, capital structure, financial reporting, and business-plan development.
Dr. David E. Toomey
Chief Science OfficerProvides medical and scientific leadership informed by experience as a physician and clinical investigator.
Nick Phillips
Chief Media OfficerLeads media, e-commerce, brand development, and market-expansion work.
Research headquarters
Continue the research—from official filings to the wider market.
Every destination is labeled so readers can distinguish official records, company communications, government guidance, and third-party research.
Med-X, Inc.
SEC filing record ↗Investor relations ↗Company news ↗MXRX listing status ↗Pest management
EPA IPM principles ↗EPA resistance guidance ↗CDC mosquito management ↗EPA biopesticides ↗Industry and growth
U.S. pest-control results ↗Grand View forecast ↗Fortune BI forecast ↗WHO vector management ↗Explore the platform
Nature-Cide ↗Nature-Cide history ↗Management team ↗Investor presentation ↗Med-X, Inc. · Reserved ticker: MXRX
Products. Field experience. Market pathways. A larger opportunity to research.
Important information
Med-X, Inc. is currently a private company and does not have a publicly traded stock symbol. The company states that it has reserved MXRX with Nasdaq for possible use following a successful future public listing. A ticker reservation is not a listing, exchange approval, or assurance that a listing will occur. Med-X, Inc. does not use the ticker MEDX and is not associated with securities identified by MEDX.
National Investor Network is owned and controlled by Med-X, Inc. This issuer-sponsored profile is informational and is not independent research, investment advice, or a recommendation to buy or sell a security. Review official SEC filings and current company information for controlling financial, offering, risk, and status disclosures.